Sep. 17 at 11:31 PM
$COYA | Fundamental & Technical Breakdown 📊🧬
• Business Overview: Clinical-stage biotechnology company developing biologics and cell therapies targeting regulatory T-cell (Treg) dysfunction.
• Profitability & Financials: Clinical-stage development company backed by a strong balance sheet with non-dilutive grant funding and strategic partnerships.
• Latest Earnings Report (Q2 Fiscal 2026): Beat EPS estimates (-
$0.28 vs. -
$0.36 exp.) and beat revenue (
$243.7K vs.
$104.3K exp.),
• Wall Street Analyst Consensus: Strong Buy consensus rating with an average 12-month price target near
$15.00–
$16.00.
• Overall Bias: Bullish (Technicals breaking out of an 8H falling wedge above
$4.41 support, supported by solid Q2 earnings beats and FDA Fast Track tailwinds).
Key Levels for Bulls & Bears:
• Bull Reclaim Trigger:
$5.00 /
$5.25
• Overhead Targets:
$5.75 /
$6.30
• Critical Support Pivot:
$4.41
• Bearish Invalidation Level:
$4.01 /
$3.70
#COYA #biotech #pharma #fundamentalanalysis #hovdid
